REQUEST A REP

NEWS & EVENTS
Watch real patient and caregiver stories about ARISTADA
Discover clinical efficacy and safety data

ARISTADA is proven effective for schizophrenia in adultsAT DISCHARGE, PUT PATIENTS ON THEIR TREATMENT TRACK FROM DAY 1

With one injection of ARISTADA INITIO and a single dose of oral aripiprazole plus ARISTADA 1064 mg, you can fully dose on day 1 for 2 months of treatment.1,2

Images are not actual patients

DISCOVER THE CLINICAL OVERVIEW and additional supportive studies.

With one injection of ARISTADA INITIO and a single dose of oral aripiprazole plus ARISTADA 1064 mg, you can fully dose on day 1 for 2 months of treatment.1,2

FULLY DOSE ON DAY 1 FOR 2 MONTHS OF TREATMENT1,2

+

ARISTADA INITIO

Reduces oral aripiprazole supplementation to 1 day1

ARISTADA INITIO® (aripiprazole lauroxil) is only to be used as a single dose to initiate ARISTADA® (aripiprazole lauroxil) treatment or as a single dose to reinitiate ARISTADA treatment following a missed dose of ARISTADA. ARISTADA INITIO is not intended for repeated dosing.1,2

testGet started
+

ARISTADA 2-MONTH DOSE

The first and only 2-month dose (1064 mg) for schizophrenia2

The longest dosing interval of ARISTADA available, ARISTADA 1064 mg can be started without prior treatment with monthly long-acting injectables.2

For patients who have never taken aripiprazole, establish tolerability with oral aripiprazole prior to initiating ARISTADA or ARISTADA INITIO.1,2

testLearn More

Initiate treatment on day 1 with one ARISTADA INITIO injection, a single dose of 30 mg oral aripiprazole, and the first dose of ARISTADA 1064 mg1,2

See Dosing

“Receiving medication every 2 months allows me not to have to think about it every day.”

- Jordan

Learn more about the clinical studies, including additional data, supporting the efficacy and safety of ARISTADA2-4

CLINICAL OVERVIEW
References: 1. ARISTADA INITIO. Package insert. Alkermes, Inc; 2020. 2. ARISTADA. Package insert. Alkermes, Inc; 2020. 3. Nasrallah HA, Aquila R, Du Y, Stanford AD, Claxton A, Weiden PJ. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectr. 2019;24(4):395-403. 4. Weiden PJ, Claxton A, Kunovac J, et al. Efficacy and safety of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients hospitalized for acute schizophrenia transitioned to outpatient care: phase 3, randomized, double-blind, active-control ALPINE study. J Clin Psychiatry. 2020;81(3):19m13207. doi:10.4088/JCP.19m13207.